http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-568550-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J73-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J73-00 |
| filingDate | 2006-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86dd9ae41036ff41b3262459bd324770 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77ec7d7eb5cdf759d7c7d57536096fc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e6a43ae5a48870e7c03dd72efb36d69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd1c31b9e481d0305e9a04e58a122568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_492da300bbce7345d30baa03c6997e38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de92d56c50c05db1c7690b532d10e672 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d440483cd0fb4c21bbdd64c382cd561 |
| publicationDate | 2011-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-568550-A |
| titleOfInvention | Polymorphs of androgen receptor modulator N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide |
| abstract | The disclosure relates to crystalline polymorphic, pseudopolymorphic and amorphous solid state forms of N-(3H-imidazo[4,5-B]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5-alpha-androst-1-en-17-beta-carboxamide represented by structural formula (I), which are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents. |
| priorityDate | 2005-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1170.